formulation

A tailored formulation with precise surfactant and stabilizer ratios stabilizes TCR-scFv bispecific proteins, addressing their instability issues, ensuring effective long-term storage and administration.

JP7587507B2Active Publication Date: 2024-11-20IMMUNOCORE LTD
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2021541283
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-04-10
Filing Date
2020-01-16
Publication Date
2024-11-20
Estimated Expiration
2040-01-16

AI Technical Summary

Technical Problem

The formulation of bispecific proteins comprising soluble T cell receptors (TCR) and scFvs poses challenges due to their complex structure and instability, particularly at low concentrations and high temperatures, leading to aggregation and degradation, which complicates long-term storage and administration.

Method used

A pharmaceutical formulation with a specific weight-to-weight ratio of surfactant to protein (0.75:1 to 1.5:1) and a stabilizer-to-bulking agent ratio greater than 1:1, using excipients like polysorbate 20, trehalose, and mannitol, maintains protein stability and prevents aggregation during storage.

Benefits of technology

The formulation ensures stability of TCR-scFv bispecific proteins at low concentrations and high temperatures, allowing for convenient and cost-effective storage and transportation, with minimal loss of activity over extended periods.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007587507000002
    Figure 0007587507000002
  • Figure 0007587507000003
    Figure 0007587507000003
  • Figure 0007587507000004
    Figure 0007587507000004
Patent Text Reader

Abstract

The present invention relates to a pharmaceutical formulation comprising (i) a therapeutically effective amount of a bispecific protein comprising a soluble T-cell receptor (TCR) and an scFV; and (ii) a surfactant. The w / w ratio of surfactant to protein is in the range of 0.75:1 to 1.5:1. The formulation may further comprise a bulking agent and / or a stabilizer. Further pharmaceutical formulations comprise (i) a therapeutically effective amount of a bispecific protein comprising a soluble T-cell receptor (TCR) and an scFV; (ii) a bulking agent; and (iii) a stabilizer. The w / w ratio of stabilizer to bulking agent may be greater than 1:1.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to formulations. In particular, the present invention relates to pharmaceutical formulations of bispecific proteins comprising a soluble T cell receptor (TCR) and an scFv. [Background technology]

[0002] Advances in biotechnology have made it possible to generate proteins for pharmaceutical use. Because proteins are larger and more complex than traditional organic and inorganic drugs (e.g., having multiple functional groups in addition to complex three-dimensional structures), formulating such proteins poses problems. For a protein to remain biologically active, a formulation must preserve intact the steric integrity of at least the core sequence of the protein's amino acids, while at the same time protecting the protein's multiple functional groups from degradation. Protein degradation pathways may involve chemical instability (e.g., any process involving modification of a protein by bond formation or cleavage resulting in a new chemical entity), or physical instability (e.g., a change in the higher order structure of a protein). Chemical instability may be the result of deamidation, racemization, hydrolysis, oxidation, beta-elimination or disulfide exchange. Physical instability may be the result of, for example, denaturation, aggregation, precipitation or adsorption. The three most common protein degradation pathways are protein aggregation, deamidation and oxidation (Cleland et al., Critical Reviews in Therapeutic Drug Carrier Systems 10(4): 307-377 (1993)).

[0003] Antibodies (including fragments and variants) are one class of therapeutic proteins for which successful pharmaceutical formulations have been described (Wang et al., J Pharm Sci. 2007 Jan;96(1):1-26.). However, the technical field for stable pharmaceutical formulations for bispecific proteins comprising soluble T-cell receptors (TCRs) and scFvs is extremely limited. Due to the known complexities of protein formulations and the many differences between TCR bispecific proteins and antibodies, the techniques developed for the formulation of antibodies cannot be expected to apply to these bispecific TCR proteins. For example, in antibody formulations, high protein concentrations (i.e., 1 mg / ml or more) are desirable to minimize the volume of pharmaceutical administered to patients while maintaining the required therapeutic effect. TCR-scFv bispecific proteins are designed to be particularly potent at low protein concentrations, so formulations with low protein concentrations (i.e., 1 mg / ml or less) are desirable. Low protein concentrations are particularly problematic. This is because even low levels of aggregation or brief contact with vial surfaces (ie, absorption losses) can result in significant loss of protein activity.

[0004] Furthermore, unlike antibodies, TCRs are known to be inherently unstable in solution, meaning that it is not easy to maintain protein stability at relatively high temperatures (e.g., -30°C or above -20°C, e.g., 2-8°C) and / or during long-term storage. Stability of therapeutic proteins at relatively high temperatures and during long-term storage is a desirable feature, allowing for convenient, low-cost transportation and storage to / at clinical facilities. Finally, glycosylation is an important consideration in antibody formulations, since changes in glycosylation can affect the rate of protein degradation. TCR-scFv bispecific proteins are generally not glycosylated, as they are produced in E. coli. Summary of the Invention [Problem to be solved by the invention]

[0005] A need exists to provide pharmaceutical formulations for TCR-scFv bispecific proteins that are particularly desirable for maintaining protein stability at low protein concentrations and during extended storage periods at relatively high temperatures. [Means for solving the problem]

[0006] In a first aspect, the present invention provides a a therapeutically effective amount of a bispecific protein comprising a soluble T cell receptor (TCR) and an scFV; and Surfactants wherein the w / w ratio of surfactant to protein is in the range of 0.75:1 to 1.5:1.

[0007] In a second aspect, the present invention provides a method for producing a semiconductor device comprising the steps of: a therapeutically effective amount of a bispecific protein comprising a soluble T cell receptor (TCR) and an scFV; Bulking agents; and Stabilizers wherein the w / w ratio of stabilizer to bulking agent is greater than 1:1. [Brief description of the drawings]

[0008] [Figure 1] FIG. 1 provides the results of SE-UPLC, AE-HPLC and CGE analysis for a formulation comprising 0.2 mg / ml TCR-scFv bispecific protein, 50 mM phosphate-citrate pH 6.5, 5% trehalose, 1% mannitol and 0.02% Tween 20. [Diagram 2] FIG. 2 provides the results of SE-UPLC, AE-HPLC and CGE analysis for a formulation comprising 0.2 mg / ml of an alternative TCR-scFv bispecific protein, 50 mM phosphate-citrate pH 6.5, 5% trehalose, 1% mannitol and 0.02% Tween 20. [Diagram 3]FIG. 3 provides the results of a light obscuration analysis for formulations comprising 0.2 mg / ml TCR-scFv bispecific protein, 50 mM phosphate-citrate pH 6.5, 5% trehalose, 1% mannitol and either 0.06%, 0.04%, 0.02%, 0.01% or 0.005% Tween 20. [Figure 4] FIG. 4 provides the results of a Design of Experiments (DoE) analysis for formulations comprising 0.2 mg / ml TCR-scFv bispecific protein, 50 mM phosphate-citrate pH 6.5, 5% trehalose, 1% mannitol and either 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07% or 0.08% Tween 20. [Diagram 5] FIG. 5 provides the results of SE-UPLC, AE-HPLC and CGE analysis for a formulation comprising 0.5 mg / ml TCR-scFv bispecific protein, 50 mM phosphate-citrate pH 7.5, 120 mM NaCl and 0.05% Tween 20. [Figure 6] FIG. 6 provides the results of a turbidity analysis for a formulation comprising 0.2 mg / ml TCR-scFv bispecific protein, 50 mM phosphate-citrate pH 6.5, 5% mannitol and 0.02% Tween in the presence or absence of 1% sucrose. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0009] In a first aspect, the present invention provides a method for producing a composition comprising: a therapeutically effective amount of a bispecific protein comprising a soluble T cell receptor (TCR) and an scFV; and Surfactants wherein the w / w ratio of surfactant to protein is in the range of 0.75:1 to 1.5:1.

[0010] The inventors have found that w / w ratios of surfactant to protein in the range of 0.75:1 to 1.5:1 result in stable formulations. Surfactants are excipients commonly used in protein formulations to prevent both protein aggregation and surface absorption. It has been shown in the art that a wide range of surfactant concentrations are adequate to prevent aggregation (0.02-2.0 mg / mL or 0.002-0.2%) and that the higher the concentration, the better the prevention of precipitation (Wang, Eur J Pharm Biopharm. 2017 May;114: 263-277). Furthermore, in known protein formulations, it is common that the weight of protein is in substantial excess relative to the weight of surfactant; for example, in formulations of the commercially available therapeutic antibodies trastuzumab (Heceptin®) and bevacizumab (Avastin®), the antibodies are present in a 50-fold or greater excess relative to the surfactant. The inventors have unexpectedly found that increasing or decreasing the w / w ratio of detergent to protein outside the narrow range of 0.75:1 to 1.5:1 in TCR-scFv bispecific protein formulations results in a substantial loss of protein stability. Without being bound by theory, the inventors hypothesize that the lower protein concentration in the formulation as a result of the high potency of the drug means that the protein is more sensitive to small changes in detergent concentration.

[0011] The w / w ratio of detergent to protein may be in the range of 0.8:1 to 1.2:1, 0.9:1 to 1.1:1 or 0.95:1 to 1.05:1. The ratio may be 0.75:1, 0.8:1, 0.85:1, 0.9:1, 0.95:1, 1:1, 1.05:1, 1.1:1, 1.15:1, 1.2:1. The preferred ratio is 1:1. The formulations of the invention may comprise one or more pharma- ceutically acceptable surfactants. Examples of pharma- ceutically acceptable surfactants include polysorbates (e.g., polysorbate 20, 40, 60 or 80); poloxamers (e.g., poloxamer 188); triton; sodium octyl glycoside; lauryl-, myristyl-, linoleyl- or stearyl-sulfobetamine; lauryl-, myristyl-, linoleyl- or stearyl-sarcosine; linoleyl-, myristyl- or cetyl-betamine; lauroamidopropyl-, cocamidopropyl-, linoleamidopropyl-, myristamidopropyl-, palmidopropyl- or isostearamidopropyl-betamine (e.g., lauroamidopropyl); myristamidopropyl-, palmidopropyl- or isostearamidopropyl-dimethylamine; sodium cocoyl methyl taurate, disodium oleyl methyl taurate, polyethyl glycol, polypropyl glycol and copolymers of ethylene and propylene glycol. Preferably, the surfactant in the formulation of the invention is a polysorbate, such as polysorbate 20 (trade name Tween® 20) or polysorbate 80 (trade name Tween® 80). More preferably, the surfactant is polysorbate 20 (Tween® 20). The surfactant may be present in a w / v concentration of 0.1% or less, such as 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%. The concentration of the surfactant may be 0.02%. The concentration of the surfactant may be 0.05%. Suitably, the surfactant is polysorbate 20 and is present in a concentration of 0.02%. The formulation of the first aspect may further comprise a bulking agent and / or a stabilising agent. Preferably the ratio of stabilising agent to bulking agent is greater than 1:1.

[0012] In a second aspect, the present invention provides a method for producing a composition comprising: a therapeutically effective amount of a bispecific protein comprising a soluble T cell receptor (TCR) and an scFV; Bulking agents; and Stabilizers wherein the w / w ratio of stabilizer to bulking agent is greater than 1:1.

[0013] The inventors have found that using a bulking agent and a stabilizing agent with a w / w ratio of stabilizer to bulking agent greater than 1:1 results in a stable formulation that is easily lyophilized. A mixture comprising a disaccharide stabilizing agent (e.g., trehalose or sucrose) and a bulking agent (e.g., mannitol) is known to be a suitable excipient for lyophilized protein formulations (Johnson, J Pharm Sci. 2002 Apr;91(4):914-22). Mannitol easily forms a crystalline structure, facilitating the production of a stable cake that does not collapse during drying. However, in the crystalline state, mannitol cannot react with proteins and may aggregate. The addition of sucrose (which forms an amorphous phase) can prevent aggregation. It has been proposed that a mannitol to sucrose weight ratio of at least 3:1 is necessary to provide a sufficient balance between cake stability and aggregation prevention; lower ratios have been shown to inhibit mannitol crystallization (Jena et al., Pharm Res. 2016 Jun;33(6):1413-25; Johnson et al., J Pharm Sci. 2002 Apr;91(4):914-22). Contrary to teachings in the art, the inventors have found that a bulking agent (e.g., mannitol) to stabilizing agent (e.g., sucrose / trehalose) ratio of less than 1:1 (preferably 1:5) results in a stable cake with minimized aggregation. The inventors hypothesize that crystalline mannitol, when present in excess, may cause excessive distortion in the structure of the TCR-scFv bispecific protein in the lyophilized state, leading to subsequent unfolding, denaturation and aggregation.

[0014] The w / w ratio of stabilizer to bulking agent may preferably range from 3:1 to 5:1, more preferably from 4:1 to 6:1. For example, the ratio may be 2:1 or 3:1 or 4:1 or 5:1 or 6:1. The ratio of stabilizer to bulking agent may preferably be about 5:1, for example 5.5:0.9 to 4.5:1. The ratio of stabilizer to bulking agent may more preferably be 5:1. The concentration of stabilizer may be in the range of 4.5 to 5.5% (w / v), for example 5%. The concentration of bulking agent used in the formulation may be in the range of 0.9 to 1.1% (w / v), for example 1%. Bulking agents are pharma- ceutically acceptable compounds that function to increase the bulk of the lyophilized cake (lyocake). Compounds that function as bulking agents are known in the art and include polyols (e.g., mannitol or sorbitol), carbohydrates, monosaccharides, polymers, or proteins. Preferably, the bulking agent is a polyol. More preferably, the bulking agent is mannitol. Preferably, the mannitol is present at a concentration of 1%.

[0015] A stabilizer is a pharma- ceutically acceptable compound that functions as a lyoprotectant / cryoprotectant upon freezing or lyophilization, thus preventing aggregation and / or other chemical or physical instability. Compounds that function as stabilizers are known in the art. Examples of stabilizers include sugars, sugar-alcohols, and amino acids. Preferably, the stabilizer is a disaccharide. More preferably, the stabilizer is trehalose or sucrose. The stabilizer may be a mixture of trehalose and sucrose. Preferably, the stabilizer is trehalose, present at a concentration of 5%. In a preferred formulation of the present invention, the stabilizer is trehalose and the bulking agent is mannitol. The w / w ratio of trehalose to mannitol is preferably 5:1.

[0016] The formulation of the present invention may further comprise a buffer. Pharmaceutically acceptable buffers are known in the art. Examples include phosphate, citrate, lysine, histidine, acetate, succinate and Tris buffers. Any of these may be used in the present invention. A suitable buffer is a phosphate-citrate buffer. The concentration of the buffer may be about 20 mM to about 50 mM, for example, 20 mM, 30 mM, 40 mM or 50 mM. Preferably, the buffer concentration is 50 mM. Preferably, the formulation comprises 50 mM of phosphate-citrate buffer. The optimum pH of a pharmaceutical formulation depends on the primary sequence of the protein and its concentration, as well as the identity and concentration of other excipients. In a preferred formulation of the present invention, the pH is in the range of about pH 6 to about pH 7, preferably 6.3 to 6.7. For example, the pH can be pH 6.0 or pH 6.1 or pH 6.2 or pH 6.3 or pH 6.4 or pH 6.5 or pH 6.6 or pH 6.7 or pH 6.8 or pH 6.9 or 7.0. pH 6.5 is preferred. pH 6.0 is also preferred.

[0017] The formulation may be an aqueous formulation. Preferably, the aqueous carrier is pharma- ceutically acceptable (safe and non-toxic for administration to humans). The aqueous carrier may be distilled water or sterile water. In some embodiments, the aqueous formulation may be frozen. Alternatively, the aqueous formulation may be lyophilized to produce a lyophilized formulation. Suitable protocols and methods for producing lyophilized pharmaceutical formulations from liquid formulations are known in the art. Methods for reconstituting lyophilized formulations prior to administration are known in the art. Briefly, lyophilization can be accomplished by freezing the formulation and then sublimating ice from the frozen contents at a suitable temperature for primary drying. Typically, primary drying is in the range of about -30 to 25°C (provided that the formulation remains frozen during the primary drying period) at a suitable pressure (typically a pressure in the range of about 0.05 mBar to about 0.5 mBar). The formulation, the size and type of container holding the sample (e.g., glass vial) and the volume of liquid will primarily affect the time required for drying, which may range from a few hours to several days. The secondary drying stage may be carried out at about 0-40° C., depending primarily on the type and size of the container and the type of protein used. The time and pressure required for secondary drying will produce a suitable lyophilized cake and will depend, for example, on temperature and other parameters. Secondary drying time is influenced by the desired residual moisture level in the formulation and typically requires at least about 5 hours (e.g., 15-24 hours). The pressure may be the same as that used during the primary drying step. Lyophilization conditions may vary depending on the formulation and vial size.

[0018] The pharmaceutical formulations of the present invention are preferably stable. The term "stable" or "stable" as used herein refers to a formulation in which one or more biophysical and / or chemical properties of the bispecific protein remain essentially unchanged upon storage at 2-8°C for an extended period of time. Extended period of time means up to at least 2 years, more preferably up to at least 5 years or longer. Additional or alternative conditions may be used as indicators of the long-term stability capability of the formulation at 2-8°C. For example, "stable" may mean that the protein remains essentially unchanged after a defined number of freeze-thaw cycles, such as at least 5 or at least 10 freeze-thaw cycles; alternatively, "stable" may mean that the protein remains essentially unchanged after shorter storage periods at higher temperatures, such as at least 1 month at a temperature of about 30°C.

[0019] The stability of the formulation may be assessed by testing one or more biophysical or chemical properties, including but not limited to appearance (color and turbidity), protein concentration, pH, presence of subvisible particles, aggregation, denaturation and protein activity. The skilled artisan will be aware of various analytical techniques that may be used to assess the stability of protein formulations. Examples include but are not limited to visual inspection, nephelometry, light obscuration, absorbance at 280 nm, capillary gel electrophoresis (CGE), anion exchange chromatography (AIEX), size exclusion chromatography (SEC), protein activity assays. For lyophilized samples, further analytical techniques may include cake physical stability assessment and moisture content measurement (e.g. by Karl Fischer evaluation). Specific techniques are further provided in the demonstration section. Preferably, the stability of the formulation is determined by assessing one or more, preferably all, of the following properties: pH, appearance, protein concentration, presence of subvisible particles, CGE, SEC, AIEX and protein activity.

[0020] The bispecific protein comprises a soluble TCR and an scFv antibody fragment, preferably fused together via a linker. The linker sequence is usually flexible in that it is made of amino acids that do not have bulky side chains that may limit its flexibility, such as glycine, alanine and serine. The usable or optimal length of the linker sequence is easily determined. In many cases, the linker sequence is about 12 amino acids or less in length, such as 10 amino acids or less or 5-10 amino acids in length. The TCR consists of two disulfide-linked chains. Each chain (α and β) is generally considered to have two domains, a variable and a constant domain (referred to as TRAV / TRBV and TRAC / TRBC, respectively). The variable domain of each chain is located at the N-terminus and comprises three complementarity determining regions (CDRs) embedded in a framework sequence. The CDRs comprise the recognition site for peptide-MHC binding. The soluble TCR may comprise TRAV and TRBV, preferably human. Soluble TCRs may contain mutations relative to natural or wild-type (preferably human) TCRs such that they have greater than physiological affinity for antigens (examples of antigens include NY-ESO, MAGEA4 or PRAME). Soluble TCRs may be heterodimeric αβ TCR polypeptide pairs, where the α and β polypeptides each have TCR variable and constant regions, but lack the TCR transmembrane and cytoplasmic regions. Non-natural disulfide bonds between residues of the constant regions of the TCR α and β polypeptides may be present. Soluble TCRs may recognize antigens presented on diseased cells (e.g. cancer cells) or cells infected with viruses or bacteria. The two chains of the soluble TCR may be produced as single chains (WO2004 / 033685) or as disulfide-linked dimers (WO03 / 020763). In one specific embodiment, the soluble TCR comprises an αβ heterodimer having TRAV and TRBV regions and an extracellular α chain TRAC constant domain sequence and an extracellular β chain TRBC1 or TRBC2 constant domain sequence. The TRAC or TRBV sequence may be modified by truncation or substitution to delete the native disulfide bond between Cys4 of exon 2 of TRAC and Cys2 of exon 2 of TRBC1 or TRBC2.The TRAC or TRBV sequence may be modified by substitution of Thr 48 of TRAC and Ser 57 of TRBC1 or TRBC2 with a cysteine ​​residue, which forms a disulfide bond between the α and β constant domains of the TCR. The constant regions of the α and β polypeptides may be linked by a native disulfide bond between Cys4 of exon 2 of TRAC*01 and Cys2 of exon 2 of TRBC1 or TRBC2. The soluble TCR may be a single chain αβ TCR polypeptide of the Vα-L-Vβ, Vβ-L-Vα, Vα-Cα-L-Vβ or Vα-L-Vβ-Cβ type, where Vα and Vβ are the TCR α and β variable regions, respectively, Cα and Cβ are the TCR α and β constant regions, respectively, and L is a linker sequence.

[0021] The term "single chain Fv" or "scFv" refers to an antibody fragment comprising the VH and VL domains of an antibody, where these domains are present in a single polypeptide chain. In general, the Fv polypeptide further comprises a polypeptide linker between the VH and VL domains that allows the scFv to form the desired structure for antigen binding. The scFv may be derived from a human antibody or may be humanized. The scFv may be derived from an antibody that recognizes CD3. In one specific embodiment, the anti-CD3 scFv may be derived from the UCHT1 antibody (Shalaby et al., J Exp Med. 1992 Jan 1;175(1):217-25, US5821337). The scFv may be fused to the N- or C-terminus of the soluble TCR. It is preferred that the scFv is fused to the N-terminus of the soluble TCR (WO2010 / 133828). The TCR-scFv bispecific protein may be present at a concentration of 1 mg / ml or less, 0.5 mg / ml or less, preferably 0.3 mg / l or less. The concentration of the TCR-scFv bispecific protein may be in the range of 0.05-0.5 mg / ml or 0.1-0.3 mg / ml, and may be 0.5, 0.4, 0.3, 0.2 or 0.1 mg / ml. The preferred concentration is 0.2 mg / ml.

[0022] Specific TCR-scFv bispecific proteins that may be included in the formulations of the invention include those disclosed in WO2011001152, WO2017 / 109496, WO2017 / 175006 and WO2018234319. A particular TCR-scFv bispecific protein of WO2011 / 001152 has an alpha chain of SEQ ID NO:45 (wherein amino acids 1-109 are replaced with SEQ ID NO:8, the amino acid at position 1 is A, and the C-terminus of the alpha chain is truncated by 8 amino acids from F196 to S203 (inclusive) based on the numbering of SEQ ID NO:45); and a beta chain of SEQ ID NO:36 (wherein residues 259-370 correspond to SEQ ID NO:27, and the amino acids at positions 1 and 2 are A and I, respectively). Formulations comprising such TCR-scFv bispecific proteins may preferably have a pH of 6.5.

[0023] One specific formulation according to the invention comprises: A TCR-scFv bispecific protein having an alpha chain of SEQ ID NO: 45 of WO2011001152 (wherein amino acids 1 to 109 have been replaced with SEQ ID NO: 8 of WO2011001152, the amino acid at position 1 is A, and the C-terminus of the alpha chain has been truncated by 8 amino acids from F196 to S203 (inclusive) based on the numbering of SEQ ID NO: 45) and a beta chain of SEQ ID NO: 36 of WO2011001152 (wherein residues 259 to 370 correspond to SEQ ID NO: 27 of WO2011001152, and the amino acids at positions 1 and 2 are A and I, respectively), present at a concentration of 0.2 mg / ml. 50mM phosphate-citrate buffer, 5% trehalose, 1% mannitol, and 0.02% w / v Polysorbate 20 and has a pH of 6.5.

[0024] In one alternative preferred embodiment, the formulation comprises: 0.5mg / ml TCR-scFv bispecific protein, such as those described in WO2017 / 109496; 50mM phosphate-citrate buffer, 5% trehalose, 1% mannitol, and 0.05% w / v Polysorbate 20 and has a pH of 6.0.

[0025] In a further alternative preferred embodiment, the formulation comprises 0.2mg / ml TCR-scFv bispecific protein, such as those described in WO2017 / 175006; 50mM phosphate-citrate buffer, 5% trehalose, 1% mannitol, and 0.02% w / v Polysorbate 20 and has a pH of 6.0. Preferably, the bispecific protein in the formulation of the invention is non-glycosylated.

[0026] In a further aspect, the present invention also provides a method for producing a composition comprising the steps of: (i) a therapeutically effective amount of a bispecific protein comprising a soluble T cell receptor (TCR) and an scFV, and (ii) a surfactant; Here, a method for producing a pharmaceutical formulation is provided, wherein the w / w ratio of surfactant to protein is in the range of 0.75:1 to 1.5:1. In a further aspect, the present invention also provides a method for producing a composition comprising the steps of: (i) formulating a therapeutically effective amount of a bispecific protein comprising a soluble T cell receptor (TCR) and an scFV, (ii) a bulking agent, and (iii) a stabilizing agent; Here, a method is provided for producing a pharmaceutical formulation, wherein the ratio of stabilizer to bulking agent is greater than 1:1.

[0027] The invention also provides a formulation of the invention for use in medicine. The formulation may be for use in a method of treating a disease including cancer or an infectious disease. The cancer may be melanoma (including, but not limited to, cutaneous or uveal melanoma (also known as intraocular melanoma), lentigo maligna melanoma, superficial spreading melanoma, acral lentigo melanoma, mucosal melanoma, nodular melanoma, polypoid melanoma, desmoplastic melanoma, amelanotic melanoma, soft-tissue melanoma, small cell melanoma with small nevus-like cells, and spitzoid melanoma). Alternatively, the cancer may be breast cancer (including triple negative), ovarian cancer, endometrial cancer, esophageal cancer, lung cancer (NSCLC and SCLC), bladder cancer, colon cancer, stomach cancer, liver cancer, pancreatic cancer, prostate cancer, connective tissue cancer (i.e., sarcoma) or head and neck cancer; or the cancer may be leukemia or lymphoma.

[0028] In a preferred embodiment, the formulations can be administered by injection, for example, intravenous injection. The formulations can be administered by continuous infusion (e.g., over hours, days, or weeks) or intermittent infusion (e.g., once, twice, or three times per week, or less frequently). Alternatively, the formulation may be adapted for administration by any other suitable route, including intratumoral, subcutaneous, intramuscular, intrathecal, enteral (including oral or rectal), inhaled or intranasal.

[0029] In a further aspect, the present invention provides a method of treating a human subject comprising administering to the human subject a therapeutically effective amount of the pharmaceutical formulation disclosed herein. Preferred features of any one aspect of the invention apply mutatis mutandis to each other aspect of the invention. Prior art documents referred to herein are incorporated to the fullest extent permitted by law.

[0030] The invention will now be described in the following non-limiting Examples, with reference to the accompanying drawings in which: FIG. 1 provides the results of SE-UPLC, AE-HPLC and CGE analysis for a formulation comprising 0.2 mg / ml TCR-scFv bispecific protein, 50 mM phosphate-citrate pH 6.5, 5% trehalose, 1% mannitol and 0.02% Tween 20. FIG. 2 provides the results of SE-UPLC, AE-HPLC and CGE analysis for a formulation comprising 0.2 mg / ml of an alternative TCR-scFv bispecific protein, 50 mM phosphate-citrate pH 6.5, 5% trehalose, 1% mannitol and 0.02% Tween 20. FIG. 3 provides the results of a light obscuration analysis for formulations comprising 0.2 mg / ml TCR-scFv bispecific protein, 50 mM phosphate-citrate pH 6.5, 5% trehalose, 1% mannitol and either 0.06%, 0.04%, 0.02%, 0.01% or 0.005% Tween 20. FIG. 4 provides the results of a Design of Experiments (DoE) analysis for formulations comprising 0.2 mg / ml TCR-scFv bispecific protein, 50 mM phosphate-citrate pH 6.5, 5% trehalose, 1% mannitol and either 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07% or 0.08% Tween 20. FIG. 5 provides the results of SE-UPLC, AE-HPLC and CGE analysis for a formulation comprising 0.5 mg / ml TCR-scFv bispecific protein, 50 mM phosphate-citrate pH 7.5, 120 mM NaCl and 0.05% Tween 20. FIG. 6 provides the results of a turbidity analysis for a formulation comprising 0.2 mg / ml TCR-scFv bispecific protein, 50 mM phosphate-citrate pH 6.5, 5% mannitol and 0.02% Tween in the presence or absence of 1% sucrose. EXAMPLES

[0031] Working Example Example 1 - Stable aqueous formulation for soluble TCR-scFv bispecific proteins A) anti-CD3 A bispecific protein comprising a soluble TCR fused to an scFv (an alpha chain of SEQ ID NO: 45 of WO2011 / 001152, where amino acids 1-109 have been replaced with SEQ ID NO: 8 of WO2011001152, where the amino acid at position 1 is A and the C-terminus of the alpha chain has been truncated by 8 amino acids from F196 to S203 (inclusive) based on the numbering of SEQ ID NO: 45) and a beta chain of SEQ ID NO: 36 of WO2011 / 001152, where residues 259-370 correspond to SEQ ID NO: 27 of WO2011 / 001152, where the amino acids at positions 1 and 2 are A and I, respectively) was prepared using known methods and buffer exchanged into formulation buffer using size exclusion chromatography (SEC). The protein was then diluted with formulation buffer to a final concentration of 0.20±0.02 mg / mL and filled into bottles in a laminar air flow (LAF) bench. The formulation buffer contained 50 mM phosphate-citrate, 5% trehalose, 1% mannitol and 0.02% Tween 20. The pH was 6.5.

[0032] Protein stability was monitored over 24 months at either <-60°C or +5°C. Stability at each temperature was assessed using various analytical methods including capillary gel electrophoresis (CGE), anion exchange high performance liquid chromatography (AE-HPLC) and size exclusion ultra performance liquid chromatography (SE-UPLC). Further evaluation included visual inspection, measurement of protein content and pH, detection of subvisible particles by light obscuration method and activity assays to confirm functionality. Protein stability was also demonstrated over 10 freeze-thaw cycles. SE-UPLC was used to detect the presence of multimers and other high molecular weight species. SE-UPLC was performed on a UPLC system using a 1.7 μm, 4.6×300 mm UPLC SE column with an isocratic mobile phase of 0.2 M phosphate pH 7.5 (0.2 ml / min). The method involves separation of protein components in a test sample on a SE column with detection by fluorescence on a UPLC system after injection of an appropriate volume onto the column. FIG. 1A shows the evaluation of purity measured by SE-UPLC at 8 time points over a period of 24 months at +5° C. Purity at 0 months was 99.2% and at 24 months was 99.3%. Minimum acceptance criteria ≧95%.

[0033] Charge-based degradation was detected using AE-HPLC. AE-HPLC was performed on an HPLC system using a 2×250 mm weak AE column with a mobile phase of phosphate pH 8.2 (0.2 ml / min). Proteins were eluted with a gradient of NaCl in phosphate (pH 8.2) buffer. The method involves separation of protein components in a test sample on an AE column with detection by fluorescence on an HPLC system after injection of an appropriate volume onto the column. Figure 1B shows the evaluation of the charge state measured by AE-HPLC at 8 time points over a period of 24 months at +5° C. The % main peak at 0 months was +3.4% compared to the reference value, and the reading at 24 months was −1.9%. This proves that the product was stable in this formulation (acceptance criteria: within ±15% of reference). CGE was used to determine the presence of low molecular weight impurities and degradants (e.g. fragments). The method was performed using chip and standard CGE. For the chip method, samples were prepared to a final concentration of 0.2 mg / mL and heated at 70° C. for 5 min. After cooling, the denatured samples were loaded onto the chip and separated on a Bioanalyzer (Agilent technologies). Standard CGE was performed on a PA 800 plus instrument equipped with a diode array detector (Beckman Coulter) using reagents from the Proteolab SDS MW analysis kit and a separation capillary (57 cm×50 μm ID, bare fused-silica). Samples were prepared to 0.2 mg / mL before dilution in SDS sample buffer and heated at 70° C. for 5 min. The analysis was read at 220 nm and migration times and % corrected peak areas were recorded. Minimum acceptance criteria ≧95%.

[0034] Figure 1C shows the evaluation of purity by CGE at 7 time points over a 24 month period at +5° C. The purity at month 0 was 99.6% and at T=24 months it was 99.7%, demonstrating that the product was stable in this formulation. Stability assessment after multiple freeze / thaw cycles was used as an additional indicator of long-term stability. Freeze-thaw cycles were performed by rapidly freezing the samples to <-60°C followed by incubation at room temperature (approximately 22°C). Stability was assessed by SE-UPLC as described above. Results showed a purity of 99.6% before 10 freeze-thaw cycles and 99.5% afterwards, indicating that the product was stable in this formulation. The visual analysis was performed according to the principles of the methods described in the Pharmacopoeias (European Pharmacopoeia 2.2.1, 2.2.2 and 2.9.20). A clear, colorless solution (essentially free of particles) was observed at 0 months and after 24 months at +5° C. In addition, no visible changes were detected after 10 freeze-thaw cycles.

[0035] Protein concentrations and pH were within ±0.02 mg / ml and ±0.2 pH units of the values ​​after 24 months. Evaluation of particles subvisible to the naked eye by laser light obscuration showed that after 24 months, particles ≥ 25 μm were present at ≤ 600 / vial and particles ≥ 10 μm were present at ≤ 6000 / vial (i.e., within the acceptance criteria). Turbidity measurements were within the acceptance range (< 3 NTU (standard of opalescence I)). These data demonstrate that the formulation was stable over an extended storage period at temperatures between 2 and 8°C. Lyophilized formulations were prepared by freezing 0.6 ml samples in 2R glass vials and holding at -45°C for 2 hours, followed by primary drying at -15°C / 0.07 mbar for 22 hours, then secondary drying at +40°C / 0.07 mbar for 23 hours. Samples were then sealed in vials with rubber stoppers under vacuum. Lyophilized samples were stored long term at +5°C. Samples were reconstituted by adding 0.6 ml of sterile water for injection to the vial and mixing.

[0036] B) A second bispecific protein comprising an alternative soluble TCR (described in WO2017 / 175006) fused to an anti-CD3 scFv was prepared to a final concentration of 0.20±0.02 mg / mL. The formulation buffer contained 20 mM phosphate-citrate, 5% trehalose, 1% mannitol and 0.02% Tween 20. The pH was 6.0. Stability evaluation was performed over a 12 month period using the same method as in Part "A". The data from SE-UPLC, AE-HPLC and CGE are shown in Figures 2A-C, respectively. Purity by SE-UPLC was 98.9% at 0 months and 99.3% at 12 months. Charge state by AE-HPLC was -12.2% main peak at 0 months and -19.5% main peak at 12 months compared to the reference (acceptance criteria: within ±20% of reference). Purity by CGE was 98.8% at 0 months and 98.3% at 12 months. In each case, extrapolation of the data indicates that stability can be predicted to be ≥24 months. Stability was also demonstrated by SE-UPLC after 10 freeze-thaw cycles. These data demonstrate that the formulation is stable during long-term storage at temperatures between 2-8°C.

[0037] Example 2 - Formulation Optimization A - Detergent to protein ratio The weight ratio of surfactant to protein was found to be an important factor in producing a stable formulation. Evidence for this was obtained from laser light obscuration (LO) measurements that assessed the presence of subvisible particles of 2 μm or larger in size after five freeze-thaw cycles. The formulation buffer contained the TCR-scFv bispecific protein of Example 1A, 50 mM phosphate-citrate, 5% trehalose, 1% mannitol and Tween 20 at one of five different concentrations. The pH was 6.5. The protein concentration was kept constant at 0.2 mg / ml. The assay was performed on a PAMAS SVSS-C or equivalent particle size determination device. Samples were analyzed neat with a pre-run volume of 0.4 ml and a measurement volume of 0.1 ml. The analysis was performed in triplicate. Particle counts were determined for particles of ≧2 μm, ≧10 μm and ≧25 μm.

[0038] FIG. 3 shows that the lowest number, and therefore the highest stability, for particle sizes ≧10 μm was obtained at a Tween-20 to protein ratio of 1. Further evidence that the surfactant to protein ratio is important was obtained from a Design of Experiments (DoE) study. In this study, the stability of the bispecific protein of Example 1A was tested under 32 different conditions at a fixed protein concentration of 0.2 mg / ml. Variables included the concentration of surfactant. In each case, the formulations were stored at +30°C ± 3°C for 1 month and the stability was monitored for 5x freeze-thaw cycles at elevated temperature. The effect of Tween 20 concentration (and thus Tween 20 / protein w / w ratio between 1 and 4) was evaluated by several analytical methods including SE-UPLC, AE-HPLC and CGE. In addition, the activity of the bispecific protein was evaluated using ELISA. The results are summarized in Figure 4.

[0039] B-Mannitol + Sucrose / Trehalose The inclusion of both mannitol and sucrose or trehalose was found to be an important factor in the formulation and necessary to provide a formulation that was easy to lyophilize. The bispecific protein of Example 1A was prepared in a formulation buffer containing 50 mM phosphate-citrate, 120 mM NaCl and 0.05% Tween 20 at a final protein concentration of 0.5 mg / ml. The pH was 7.5. Stability was assessed using the same methods as described in Example 1. Figures 5A-C show SE-UPLC, AE-HPLC and CGE data over a 36 month period at +5°C. The data show that the formulation was not stable after 12 months. Subsequently, using DoE methodology, it was found that the addition of either 5% mannitol or 5% sucrose improved stability. The absence of NaCl was also preferred. However, the formulation containing 5% mannitol produced high levels of aggregation after 10 freeze-thaw cycles as determined by laser light obscuration (LO) method and turbidity (NTU) measurements. Turbidity was measured nephelometrically using a turbidimeter and calibration against known turbidity standards. FIG. 6 demonstrates that the addition of 1% sucrose reduced freeze-thaw induced aggregation.

[0040] To further investigate the ease of lyophilization, a formulation was prepared containing 50 mM phosphate-citrate, 5% mannitol, 1% sucrose, 0.02% Tween 20 with a final protein concentration of 0.2 mg / ml. The pH was 6.5. Samples were lyophilized in glass DP lyo vials and stored at 50°C, 25°C and 40°C for 1, 2 and 3 months. Samples were then rehydrated by adding 0.5 ml of ultrapure water and incubated at room temperature for 1 hour and then evaluated using several techniques including turbidity, laser light obscuration, SE-UPLC, AE-HLPC, CGE and protein activity. Increased aggregation and significant loss of protein activity was observed at higher temperatures, indicating that this formulation is not suitable for long-term storage. It was subsequently found that the ratio of mannitol to sucrose was important in maintaining stability, and trehalose was interchangeable with sucrose, to improve long-term stability and maintain liquid stability. Formulations containing the bispecific protein of Example 1A with two different mannitol / sucrose ratios were evaluated after lyophilization and storage at 25°C or 40°C for four weeks. Stability was evaluated using several techniques, including turbidity, laser light obscuration, SE-UPLC, AE-HLPC, and protein activity. Turbidity data is shown in the table below. The data indicates that higher concentrations of mannitol compared to sucrose result in increased aggregation.

[0041] [Table 1]

Claims

1. a therapeutically effective amount of a bispecific protein comprising a soluble T cell receptor (TCR) and an scFV fused to each other via a linker; and Surfactants Bulking Agent Stabilizers comprising the w / w ratio of said surfactant to said protein is in the range of 0.75:1 to 1.5:1, and the ratio of said stabilizing agent to said bulking agent is greater than 1:1; the bispecific protein is present at a concentration of 1 mg / ml or less; A pharmaceutical formulation, wherein the surfactant is a polysorbate, the bulking agent is mannitol, and the stabilizing agent is sucrose or trehalose, or a mixture of sucrose and trehalose.

2. 2. The formulation of claim 1, wherein the w / w ratio of surfactant to protein is 1:

1.

3. 3. The formulation of claim 1 or 2, wherein the ratio of stabilizer to bulking agent is greater than 1.5:

1.

4. 4. The formulation of claim 3, wherein the ratio of stabilizer to bulking agent is within the range of 3:1 to 7:

1.

5. A formulation according to any one of claims 1 to 4, wherein the surfactant is present in a w / v concentration of 0.1% or less.

6. A formulation according to any one of claims 1 to 4, wherein the surfactant is present in a w / v concentration of 0.02% or less.

7. The formulation according to any one of claims 1 to 6, wherein the polysorbate is polysorbate 20.

8. The formulation according to any one of claims 1 to 7, wherein the concentration of the bulking agent is in the range of 0.9 to 1.1% (w / v).

9. The formulation according to any one of claims 1 to 8, wherein the concentration of the bulking agent is 1% (w / v).

10. The formulation according to any one of claims 1 to 9, wherein the concentration of the stabilizing agent is within the range of 4.5 to 5.5% (w / v).

11. The formulation according to any one of claims 1 to 10, wherein the concentration of the stabilizing agent is 5% (w / v).

12. The formulation according to any one of claims 1 to 11, further comprising a buffering agent.

13. 13. The formulation of claim 12, wherein the buffer is phosphate / citrate.

14. The formulation according to claim 12 or 13, wherein the concentration of the buffer is from 20 mM to 50 mM.

15. 14. The formulation of claim 12 or 13, wherein the concentration of the buffer is 50 mM.

16. A formulation according to any one of claims 1 to 15, having a pH in the range of 6 to 7.

17. 16. A formulation according to any one of claims 1 to 15, having a pH of 6.0, 6.5 or 6.

8.

18. 18. The formulation of any one of claims 1 to 17, wherein the concentration of the bispecific protein is 0.05 to 0.5 mg / ml.

19. 18. The formulation of any one of claims 1 to 17, wherein the concentration of the bispecific protein is 0.2 mg / ml.

20. (a) a bispecific protein comprising: (i) an alpha chain having the following sequence: (ii) a beta chain having the sequence: AIQMTQSPSSLSASVGDRVTITCRASQDIRNYLNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQGNTLPWTFGQGTKVEIKGGGGSGGGGSGGGGSGGG GSGGGSEVQLVESGGGLVQPGGSLRLSCAASGYSFTGYTMNWVRQAPGKGLEWVALINPYKGVSTYNQKFKDRFTISVDKSKNTAYLQMNSLRAEDTAVYYCARSGYYGDSDWYFDVWGQGTLVTV SSGGGGSDGGITQSPKYLFRKEGQNVTLSCEQNLNHDAMYWYRQDPGQGLRLIYYSQIMGDEQKGDIAEGYSVSREKKESFPLTVTSAQKNPTAFYLCASSWWTGGASPISFGPGTRLTVTEDLKN VFPPEVAVFEPSEAEISHTQKATLVCLATGFYPDHVELSWWVNGKEVHSGVCTDPQPLKEQPALNDSRYALSSRLRVSATFWQDPRNHFRCQVQFYGLSENDEWTQDRAKPVTQIVSAEAWGRAD; or (b) the bispecific protein comprises: (i) an alpha chain having the following sequence: (ii) a beta chain having the sequence: AIQMTQSPSSLSASVGDRVTITCRASQDIRNYLNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQGNTLPWTFGQGTKVEIKGGGGSGGGGSGGGGSGGG GSGGGSEVQLVESGGGLVQPGGSLRLSCAASGYSFTGYTMNWVRQAPGKGLEWVALINPYKGVSTYNQKFKDRFTISVDKSKNTAYLQMNSLRAEDTAVYYCARSGYYGDSDWYFDVWGQGTLVTV SSGGGGSDGGITQSPKYLFRKEGQNVTLSCEQNLNHDAMYWYRQDPGQGLRLIYYSQIMGDEQKGDIAEGYSVSREKKESFPLTVTSAQKNPTAFYLCASSWWTGGASPIRFGPGTRLTVTEDLKN VFPPEVAVFEPSEAEISHTQKATLVCLATGFYPDHVELSWWVNGKEVHSGVCTDPQPLKEQPALNDSRYALSSRLRVSATFWQDPRNHFRCQVQFYGLSENDEWTQDRAKPVTQIVSAEAWGRAD; or (c) the bispecific protein comprises: (i) an alpha chain having the following sequence: (ii) a beta chain having the sequence: AIQMTQSPSSLSASVGDRVTITCRASQDIRNYLNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQGNTLPWTFGQGTKVEIKGGGGSGGGGSGGGGSGGG GSGGGSEVQLVESGGGLVQPGGSLRLSCAASGYSFTGYTMNWVRQAPGKGLEWVALINPYKGVSTYNQKFKDRFTISVDKSKNTAYLQMNSLRAEDTAVYYCARSGYYGDSDWYFDVWGQGTLVTV SSGGGGSDGGITQSPKYLFRKEGQNVTLSCEQNLNHDAMYWYRQDPGQGLRLIYYSQIMGDEQKGDIAEGYSVSREKKESFPLTVTSAQKNPTAFYLCASSWWTGGSAPIRFGPGTRLTVTEDLKN VFPPEVAVFEPSEAEISHTQKATLVCLATGFYPDHVELSWWVNGKEVHSGVCTDPQPLKEQPALNDSRYALSSRLRVSATFWQDPRNHFRCQVQFYGLSENDEWTQDRAKPVTQIVSAEAWGRAD; and the bispecific protein preferably has (i) an alpha chain having the following sequence: (ii) a beta chain having the sequence: AIQMTQSPSSLSASVGDRVTITCRASQDIRNYLNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQGNTLPWTFGQGTKVEIKGGGGSGGGGSGGGGSGGG GSGGGSEVQLVESGGGLVQPGGSLRLSCAASGYSFTGYTMNWVRQAPGKGLEWVALINPYKGVSTYNQKFKDRFTISVDKSKNTAYLQMNSLRAEDTAVYYCARSGYYGDSDWYFDVWGQGTLVTV SSGGGGSDGGITQSPKYLFRKEGQNVTLSCEQNLNHDAMYWYRQDPGQGLRLIYYSQIMGDEQKGDIAEGYSVSREKKESFPLTVTSAQKNPTAFYLCASSWWTGGASPIRFGPGTRLTVTEDLK NVFPPEVAVFEPSEAEISHTQKATLVCLATGFYPDHVELSWWVNGKEVHSGVCTDPQPLKEQPALNDSRYALSSRLRVSATFWQDPRNHFRCQVQFYGLSENDEWTQDRAKPVTQIVSAEAWGRAD The formulation according to any one of claims 1 to 19, having the formula:

21. (a) a bispecific protein comprising: (i) an alpha chain having the following sequence: AQQGEEDPQALSIQEGENATMNCSYKTSINNLQWYRQNSGRGLVHLILIRSNEREKHSGRLRVTLDTSKKSSSLLITASRAADTASYFCATDGSTPMQFGKGTRLSVIANIQKPDPAVYQLRDSKSSDKSVCLFTDFDSQTNVSQSKDSDVYITDKCVLDMRSMDFKSNSAVAWSNKSDFACANAFNNSIIPEDT (ii) a β-strand having the following sequence: AIQMTQSPSSLSASVGDRVTITCRASQDIRNYLNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQGNTLPWTFGQGTKVEIKGGGGSGGGGSGGGGSGGG GSGGGSEVQLVESGGGLVQPGGSLRLSCAASGYSFTGYTMNWVRQAPGKGLEWVALINPYKGVSTYNQKFKDRFTISVDKSKNTAYLQMNSLRAEDTAVYYCARSGYYGDSDWYFDVWGQGTLVT VSSGGGGSDGGITQSPKYLFRKEGQNVTLSCEQNLNHDAMYWYRQDPGQGLRLIYYSWAQGDFQKGDIAEGYSVSREKKESFPLTVTSAQKNPTAFYLCASSWGAPYEQYFGPGTRLTVTEDLKN VFPPEVAVFEPSEAEISHTQKATLVCLATGFYPDHVELSWWVNGKEVHSGVCTDPQPLKEQPALNDSRYALSSRLRVSATFWQDPRNHFRCQVQFYGLSENDEWTQDRAKPVTQIVSAEAWGRAD The formulation according to any one of claims 1 to 19, having the formula:

22. 50mM phosphate-citrate buffer, 5% trehalose, 1% mannitol, and 0.02% w / v Polysorbate 20 and having a pH of 6.0, 6.5 or 6.8 and a concentration of the bispecific protein of 0.2 mg / ml.

23. A 20 mM phosphate-citrate buffer. 5% trehalose, 1% mannitol, and 0.02% w / v Polysorbate 20 and having a pH of 6.0, 6.5 or 6.8 and a concentration of the bispecific protein of 0.2 mg / ml.

24. The formulation according to any one of claims 1 to 23, which is an aqueous solution.

25. The formulation according to any one of claims 1 to 24, which is lyophilized.

26. The formulation of any one of claims 1 to 25, wherein the soluble TCR recognises an antigen presented on diseased cells.

27. The formulation according to any one of claims 1 to 25, wherein the soluble TCR recognizes an antigen presented on a cancer cell, or a cell infected with a virus or bacteria.

28. A formulation according to any one of claims 1 to 27, wherein the soluble TCR has an affinity which exceeds physiological affinity.

29. The formulation according to any one of claims 1 to 28, wherein the antigen is PRAME.

30. (i) a therapeutically effective amount of a bispecific protein comprising a soluble T cell receptor (TCR) and an scFV fused to each other via a linker; (ii) a surfactant; (iii) a bulking agent; and (iv) a stabilizing agent, wherein the w / w ratio of the surfactant to the protein is within the range of 0.75:1 to 1.5:1; the ratio of said stabilizing agent to said bulking agent is greater than 1:1; the bispecific protein is present at a concentration of 1 mg / ml or less; 11. A method for producing an aqueous medicament, wherein the surfactant is a polysorbate, the bulking agent is mannitol, and the stabilizing agent is sucrose or trehalose, or a mixture of sucrose and trehalose.

31. A method according to claim 30, modified by the features according to any one of claims 2 to 29.

32. A formulation according to any one of claims 1 to 29 for use in medicine.

33. 33. The formulation of claim 32 for use in a method for treating cancer, preferably melanoma.

Citation Information

Patent Citations

  • Pharmaceutical compositions comprising bispecific antibody constructs for improved storage and administration

    JP2018188437A